The efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumonia

Clinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200426047206N2

Enrollment

Registered

2020-07-06

Start date

2020-07-22

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. Severe Acute Respiratory Syndrome coronavirus

Interventions

Intervention 1: Intervention group: This group receiving mesenchymal stem cells. In this group, patients are received 1 million Umbilical core-derived MSCc/BW by intravenous injection (provided by vo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Positive PCR test Age between 18-70 years patient with acute respiratory infectious symptoms and severe lung involvement

Exclusion criteria

Exclusion criteria: Sepsis Pregnancy Cancer

Design outcomes

Primary

Measure	Time frame
Patient respiratory status. Timepoint: ?????? ?? ??? ?? ????. Method of measurement: Using CT scan image, physical examination, oxygen saturation percentage.;Inflammatory factors. Timepoint: Before and two week after intervention. Method of measurement: Elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Khazaei

Hamedan University of Medical Sciences

salman.khazaei61@gmail.com+98 81 3838 0548

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026